IP Library Granted Patent US 10,849,931
Granted Patent B2
US 10,849,931 · App. 13/250,086 · Granted Dec 1, 2020

Compositions and methods for platelet enriched fibrin constructs

Inventors: Mehmet Z. Sengun (Canton, MA); William Parrish (Hudson, MA); Gregory R. Whittaker (Stoneham, MA); Douglas A. Fifolt (Wrentham, MA); Brooks J. Story (Franklin, MA)
Assignee: DEPUY SYNTHES PRODUCTS, INC
A61K35/17A61K35/14A61K35/19A61K38/18A61K38/1808A61K38/1825A61K38/1841A61K38/1866A61K38/1875A61K38/363A61K38/55A61L15/32A61L27/225A61L27/38A61L27/54A61L2300/414
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,849,931
App. No.
13/250,086
Granted
Dec 1, 2020
Kind
B2
Abstract

Compositions and methods are provided for tissue constructs that promote wound healing. The composition comprises a dimensionally stable fibrin construct for local administration to a wound site or region. In one embodiment, the fibrin construct is a wound healing composition, including components that promote wound healing, such as platelets, growth factors, white blood cells and fibrin clots. In another embodiment, the tissue treatment composition includes (i) aggregated fibrin, (ii) blood cells, and (iii) optionally, growth factors and/or other proteins.

Claims (17)

1. A method of reproducibly preparing a growth factor enriched fibrin construct, comprising:

(a) collecting a human blood sample comprising unaggregated fibrin, wherein collecting the blood sample comprises exposing the blood sample to an anti-coagulant;

(b) mixing the blood sample in a borosilicate glass container with a coagulation activator consisting of a calcium salt to initiate aggregation of the fibrin;

(c) exposing the blood mixture to a separation force, thereby producing a dimensionally stable, suturable growth factor enriched fibrin construct comprising a fibrin layer, a platelet layer and a red blood cell layer, wherein said separation force is a single centrifugation with a speed of about 2000 g to about 3,000 g;

wherein the fibrin construct has a growth factor enriched surface concentrated with blood cells and platelets and an opposed, growth factor depleted surface; wherein the growth factor enriched surface is capable of releasing a growth factor and wherein the released growth factor comprises at least about 5 ng of vascular endothelial growth factor (VEGF) within 24 hours.

2. The method of claim 1 , wherein the growth factor depleted surface is substantially lacking in blood cells.

3. The method of claim 1 , wherein the growth factor depleted surface is substantially lacking in red blood cells.

4. The method of claim 1 , wherein the growth factor depleted surface includes white blood cells.

5. The method of claim 1 , wherein the blood cells comprise white blood cells and platelets.

6. The method of claim 1 , wherein the step of collecting the blood sample comprises obtaining blood from a single donor.

7. The method of claim 1 , wherein the step of collecting the blood sample comprises obtaining blood from multiple donors.

8. The method of claim 1 , wherein the anti-coagulant is anticoagulant citrate dextrose solution A and the coagulation activator is calcium chloride.

9. The method of claim 1 , further comprising removing excess liquid from the fibrin construct by blotting the fibrin construct on an absorbent material.

10. The method of claim 1 , further comprising folding the fibrin construct upon itself to form a folded construct such that adjacent halves of the growth factor enriched surface contact each other and form an inner portion of the folded construct while the growth factor depleted surface forms an outer portion of the folded construct.

11. The method of claim 1 , further comprising forming a multilayered construct by layering a second fibrin construct on top of the first fibrin construct such that the growth factor enriched surfaces of each construct are in contact with each other and the growth factor depleted surfaces of each of the constructs form outer surfaces of the multilayered construct.

12. The method of claim 1 , further comprising cross-linking the fibrin construct.

13. The method of claim 1 , wherein a height of the fibrin plug layer is about 40% to 55% of a height of the plasma layer.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2019
From: SYNTHES USA, LLC
To: DEPUY SPINE, LLC
Reel/Frame 048829/0673 →
CHANGE OF NAME Recorded Jan 31, 2019
From: DEPUY SYNTHES PRODUCTS, LLC
To: DEPUY SYNTHES PRODUCTS, INC
Reel/Frame 048198/0563 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2019
From: DEPUY MITEK HOLDING CORPORATION
To: SYNTHES USA, LLC
Reel/Frame 048198/0860 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2019
From: DEPUY MITEK, LLC
To: DEPUY SYNTHES SALES, INC.
Reel/Frame 048197/0069 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2019
From: DEPUY SYNTHES SALES INC.
To: DEPUY SYNTHES PRODUCTS, INC.
Reel/Frame 048197/0142 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2019
From: DEPUY MITEK, LLC
To: DEPUY MITEK HOLDING CORPORATION
Reel/Frame 048197/0861 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2019
From: DEPUY SPINE, LLC
To: DEPUY SYNTHES PRODUCTS, LLC
Reel/Frame 048198/0497 →
CHANGE OF NAME Recorded Sep 2, 2014
From: DEPUY MITEK, INC.
To: DEPUY MITEK, LLC
Reel/Frame 033665/0633 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2011
From: SENGUN, MEHMET Z.; PARRISH, WILLIAM; WHITTAKER, GREGORY R.; FIFOLT, DOUGLAS A.; STORY, BROOKS J.
To: DEPUY MITEK, INC.
Reel/Frame 027285/0871 →